11039 studies found for:    NCI
Show Display Options
Rank Status Study
1 Not yet recruiting Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia
Conditions: Chronic Atrophic Gastritis;   Intestinal Metaplasia of Gastric Mucosa
Interventions: Drug: Curcumin;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment
2 Not yet recruiting Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
Conditions: Childhood Brain Stem Neoplasm;   Childhood Lymphoma;   Childhood Solid Neoplasm;   Pineal Region Neoplasm;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Visual Pathway Glioma;   Refractory Central Nervous System Neoplasm
Interventions: Drug: Entinostat;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
3 Not yet recruiting Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery
Condition: Desmoplastic Melanoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Procedure: Therapeutic Conventional Surgery
4 Not yet recruiting Cisplatin, Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma
Conditions: Stage III Hypopharyngeal Squamous Cell Carcinoma;   Stage III Laryngeal Squamous Cell Carcinoma;   Stage III Oral Cavity Squamous Cell Carcinoma;   Stage III Oropharyngeal Squamous Cell Carcinoma;   Stage IVA Hypopharyngeal Squamous Cell Carcinoma;   Stage IVA Laryngeal Squamous Cell Carcinoma;   Stage IVA Oral Cavity Squamous Cell Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Hypopharyngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Squamous Cell Carcinoma;   Stage IVB Oral Cavity Squamous Cell Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma
Interventions: Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Radiation: Radiation Therapy
5 Recruiting Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Conditions: Recurrent Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma
Interventions: Drug: Cabozantinib S-malate;   Drug: Crizotinib;   Other: Laboratory Biomarker Analysis;   Drug: Sunitinib Malate;   Drug: Volitinib
6 Not yet recruiting Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis
Conditions: Acute Pancreatitis;   Chronic Pancreatitis;   Recurrent Disease
Interventions: Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment;   Drug: Simvastatin
7 Not yet recruiting Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Docetaxel;   Other: Laboratory Biomarker Analysis;   Drug: Trametinib
8 Not yet recruiting Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer
Condition: Ductal Breast Carcinoma In Situ
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Nelipepimut-S Plus GM-CSF Vaccine;   Biological: Sargramostim
9 Not yet recruiting Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Conditions: Acute Adult T-Cell Leukemia/Lymphoma;   Adult T-Cell Leukemia/Lymphoma;   Chronic Adult T-Cell Leukemia/Lymphoma;   HTLV-1 Infection;   Lymphomatous Adult T-Cell Leukemia/Lymphoma;   Recurrent Adult T-Cell Leukemia/Lymphoma;   Smoldering Adult T-Cell Leukemia/Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Pharmacogenomic Study
10 Not yet recruiting Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Neuroendocrine Neoplasm;   Progesterone Receptor Negative;   Stage IIB Cervical Cancer;   Stage IIIA Cervical Cancer;   Stage IIIB Cervical Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Cervical Cancer;   Stage IV Gastric Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Ovarian Cancer;   Stage IV Small Cell Lung Carcinoma;   Triple-Negative Breast Carcinoma
Interventions: Drug: Ferumoxytol;   Other: Laboratory Biomarker Analysis;   Drug: Liposomal Irinotecan;   Procedure: Magnetic Resonance Imaging;   Drug: Veliparib
11 Not yet recruiting Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: High Grade Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Tumor;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Drug: ATR Kinase Inhibitor VX-970;   Drug: Carboplatin;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
12 Not yet recruiting Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer
Conditions: Adult Solid Neoplasm;   Estrogen Receptor Negative;   Fallopian Tube Serous Neoplasm;   HER2/Neu Negative;   Ovarian Serous Adenocarcinoma;   Ovarian Serous Tumor;   Primary Peritoneal Serous Adenocarcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Triple-Negative Breast Carcinoma
Interventions: Drug: Hsp90 Inhibitor AT13387;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Talazoparib
13 Recruiting Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
Conditions: Breast Carcinoma;   Neuropathy
Intervention: Other: Laboratory Biomarker Analysis
14 Recruiting Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
Conditions: Breast Carcinoma;   Cardiovascular Complication
Intervention: Other: Laboratory Biomarker Analysis
15 Recruiting Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
Conditions: Breast Carcinoma;   Hypertension
Intervention: Other: Laboratory Biomarker Analysis
16 Recruiting Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Conditions: High Grade Sarcoma;   Metastatic Leiomyosarcoma;   Metastatic Malignant Peripheral Nerve Sheath Tumor;   Metastatic Synovial Sarcoma;   Metastatic Undifferentiated Pleomorphic Sarcoma;   Myxofibrosarcoma;   Recurrent Leiomyosarcoma;   Recurrent Malignant Peripheral Nerve Sheath Tumor;   Recurrent Synovial Sarcoma;   Recurrent Undifferentiated Pleomorphic Sarcoma;   Uterine Corpus Leiomyosarcoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride;   Drug: Sapanisertib
17 Not yet recruiting Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer
Conditions: Estrogen Receptor Positive;   Postmenopausal;   Stage 0 Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer
Interventions: Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment;   Procedure: Therapeutic Conventional Surgery
18 Not yet recruiting Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer
Conditions: Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
19 Not yet recruiting VX-970 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: Adult Solid Neoplasm;   Metastatic Malignant Neoplasm;   Refractory Malignant Neoplasm;   Unresectable Malignant Neoplasm
Interventions: Drug: ATR Kinase Inhibitor VX-970;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
20 Not yet recruiting Nivolumab in Treating Patients With HIgh-Risk Non-Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Stage I Renal Cell Cancer;   Stage II Renal Cell Cancer;   Stage III Renal Cell Cancer
Interventions: Procedure: Conventional Surgery;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years